JUICE at ASCO 2015 —On the Shoulder of Giants: Chronic Lymphocytic Leukemia—Evolution of Targeted Therapy and Immunotherapy

By | 2016-11-04T16:57:08+00:00 June 8, 2015|Events, Healthcare Trends, Insights, Oncology, Viewpoints|

JUICE Pharma Worldwide was in Chicago to report on the proceedings of the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Medical Director Florian Brey, MD, and the JUICE team share the latest developments and research advances in cancer treatment.

Florian shares why patients with chronic lymphocytic leukemia may finally have more hope for progression-free and overall survival during ASCO 2015:

“The first day of ASCO is almost over. Traditionally, some of the most interesting items on the agenda of this day are the extended education sessions, for instance, one about leukemia and the evolution of chemotherapy, targeted therapy, and immunotherapy. The speaker called it the “pinnacle of chemo” and what he meant was that only after 2000 the sophisticated combination of chemotherapies with those newer therapies have turned the page for those patients and extended progression-free and overall survival.”

About the Author:

Florian Brey, MD, PhD
VP, Scientific Strategy/Medical Director

Leave A Comment